Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11364
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Packham, David K | en |
dc.contributor.author | Alves, Tahira P | en |
dc.contributor.author | Dwyer, Jamie P | en |
dc.contributor.author | Atkins, Robert | en |
dc.contributor.author | de Zeeuw, Dick | en |
dc.contributor.author | Cooper, Mark E | en |
dc.contributor.author | Shahinfar, Shahnaz | en |
dc.contributor.author | Lewis, Julia B | en |
dc.contributor.author | Lambers Heerspink, Hiddo J | en |
dc.date.accessioned | 2015-05-16T00:57:16Z | |
dc.date.available | 2015-05-16T00:57:16Z | |
dc.date.issued | 2011-11-03 | en |
dc.identifier.citation | American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation 2011; 59(1): 75-83 | en |
dc.identifier.govdoc | 22051245 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/11364 | en |
dc.description.abstract | Previous studies have shown that patients with chronic kidney disease, including those with diabetic nephropathy, are more likely to die of cardiovascular disease than reach end-stage renal disease (ESRD). This analysis was conducted to determine whether ESRD is a more common outcome than cardiovascular death in patients with type 2 diabetic nephropathy, significant proteinuria, and decreased kidney function who were selected for participation in a clinical trial.Retrospective analysis of the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database derived from 2 prospective randomized controlled clinical trials (IDNT [Irbesartan Diabetic Nephropathy Trial] and RENAAL [Reduction of Endpoints in Non-Insulin-dependent Diabetes With the Angiotensin II Antagonist Losartan]).3,228 adult patients with type 2 diabetic nephropathy from IDNT and RENAAL were combined to establish the DIAMETRIC database. This is the largest global source of clinical information for patients with type 2 diabetic nephropathy who have decreased kidney function and significant proteinuria.Angiotensin receptor blocker versus non-angiotensin receptor blocker therapy to slow the progression of type 2 diabetic nephropathy (in the prospective trials).Incidence rates of ESRD, cardiovascular death, and all-cause mortality.Mean follow-up was 2.8 years; 19.5% of patients developed ESRD, approximately 2.5 times the incidence of cardiovascular death and 1.5 times the incidence of all-cause mortality. ESRD was more common than cardiovascular death in all subgroups analyzed with the exception of participants with low levels of albuminuria (albumin excretion <1.0 g/g) and well-preserved levels of kidney function (estimated glomerular filtration rate >45 mL/min/1.73 m(2)) at baseline.All participants were included in a prospective clinical trial.Patients with type 2 diabetic nephropathy, characterized by decreased kidney function and significant proteinuria, are more likely to reach ESRD than die during 3 years' mean follow-up. Given the rapidly increasing number of cases of type 2 diabetes worldwide, this has implications for predicting future renal replacement therapy requirements. | en |
dc.language.iso | en | en |
dc.subject.other | Cardiovascular Diseases.etiology.mortality | en |
dc.subject.other | Databases, Factual | en |
dc.subject.other | Diabetes Mellitus, Type 2.complications | en |
dc.subject.other | Diabetic Nephropathies.complications | en |
dc.subject.other | Female | en |
dc.subject.other | Humans | en |
dc.subject.other | Incidence | en |
dc.subject.other | Kidney Failure, Chronic.epidemiology.etiology | en |
dc.subject.other | Male | en |
dc.subject.other | Middle Aged | en |
dc.subject.other | Proteinuria.complications | en |
dc.subject.other | Retrospective Studies | en |
dc.title | Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | American journal of kidney diseases : the official journal of the National Kidney Foundation | en |
dc.identifier.affiliation | Melbourne Renal Research Group, Royal Melbourne Hospital, Nephrology and Austin Hospital, Nephrology, Melbourne, Australia | en |
dc.identifier.doi | 10.1053/j.ajkd.2011.09.017 | en |
dc.description.pages | 75-83 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/22051245 | en |
dc.type.austin | Journal Article | en |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.